Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
POU6F2 antisense RNA 2 (POU6F2-AS2)
- Target
- POU6F2-AS2
- Molecular classification
- Long noncoding RNA (lncRNA), Antisense RNA
01
Overview
POU6F2 antisense RNA 2 (POU6F2-AS2) is a cytoplasmic long noncoding RNA expressed at significantly higher levels in NSCLC tumors compared to adjacent normal tissue[1][2]. Functionally, it acts as a *competitive endogenous RNA (ceRNA)*, sponging miR-125b-5p, which leads to de-repression and increased expression of E2F transcription factor 3 (E2F3), a driver of cell proliferation, colony formation, and tumor cell motility[1][2]. Knockdown of POU6F2-AS2 inhibits these cancer-promoting processes. Its high expression is correlated with more aggressive disease and poor prognosis, suggesting utility as both a disease biomarker and a candidate therapeutic target in lung cancer[1][2].
- Other names
- FLJ12971POU6F2-AS2
02
Mechanism of action
Not applicable for approved drugs. Mechanistically, antisense oligonucleotides, RNA interference, or targeted lncRNA inhibitors *could* theoretically be used to inhibit its function, but these are preclinical strategies and not validated therapies.
03
Biological functions
Acts as a microRNA sponge (miR-125b-5p)Regulates cellular proliferationModulates cell migration and invasionInfluences oncogenic transcription factor expression (notably E2F3)
04
Disease associations
Cancer (specifically, non-small-cell lung cancer—NSCLC; also upregulated in lung adenocarcinoma and squamous cell carcinoma)Potential role in other malignancies as supported by lncRNA family roles, but direct evidence focused on lung cancer
05
Safety considerations
Not definedpotential challenges include specificity of lncRNA-targeted therapies and off-target effects, as is common for lncRNAs
06
Biomarkers
POU6F2-AS2 expression itself is a potential biomarker for NSCLC diagnosis and prognosisalso may predict aggressive phenotypes
Beyond the preview
Go deeper on POU6F2 antisense RNA 2 (POU6F2-AS2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on POU6F2 antisense RNA 2 (POU6F2-AS2).